Best Dividend Stocks of 2026
Photo by Pexels Contributor on Pexels
The 10-year Treasury sits near 4.0%, and that has reset what counts as a competitive dividend yield. A stock yielding 2.5% no longer wins on yield alone — it has to add real dividend growth or it loses to a bond ladder. That has reshuffled the dividend leaderboard in 2026: yield is necessary but not sufficient, and our ranking now weights dividend growth and payout safety as heavily as headline yield.
We screened the dividend aristocrats and S&P 500 high-yielders for free-cash-flow coverage above 1.5x, debt-to-EBITDA below 3x, and at least five years of consecutive dividend increases. The result is a 10-stock list where the average yield is 3.4% and the trailing five-year dividend CAGR exceeds 6% — well above the 10-year inflation breakeven of 2.4%.
How We Ranked
Our ranking weighting: 30% dividend safety (FCF coverage, payout ratio, balance sheet), 25% yield, 25% dividend growth track record, 10% sector diversification, and 10% valuation. We excluded MLPs, BDCs, and most REITs from the core list to keep tax treatment consistent for typical retail investors. Yields below are quoted as forward yield based on the most recent declared dividend annualized.
| Rank | Ticker | Sector | Forward Yield | 5-Yr Div CAGR | Payout Ratio |
|---|---|---|---|---|---|
| 1 | JNJ | Healthcare | 3.0% | 5.7% | 47% |
| 2 | KO | Consumer Staples | 2.9% | 4.0% | 67% |
| 3 | PG | Consumer Staples | 2.4% | 5.5% | 60% |
| 4 | ABBV | Pharma | 3.4% | 7.5% | 52% |
| 5 | CVX | Energy | 4.1% | 5.9% | 58% |
| 6 | MO | Tobacco | 7.8% | 6.5% | 75% |
| 7 | O | REIT | 5.5% | 3.5% | 76% (AFFO) |
| 8 | IBM | Tech | 3.2% | 1.5% | 65% |
| 9 | T | Telecom | 5.6% | (4.0%) | 55% |
| 10 | KMB | Consumer Staples | 3.5% | 3.8% | 64% |
Affiliate disclosure: Finace Stoks may earn a commission when you sign up through broker links in this article. This never affects our rankings — every stock is reviewed on the same scoring rubric.
1. Johnson & Johnson (JNJ)
Post-Kenvue spin, JNJ is a focused pharma and medtech compounder. The 60+ year dividend record and 47% payout ratio give an unusual combination of yield and safety.
Pros: Fortress balance sheet, diversified pharma, 60+ years of increases. Cons: Litigation overhang, slower growth post-spin. ➡️ Trade JNJ at Fidelity
2. Coca-Cola (KO)
Buffett’s favorite for a reason. Pricing power, global distribution, and a 4% dividend CAGR keep this on the core list despite a yield only modestly above the 10-year.
Pros: Brand moat, global revenue mix, recession-resistant. Cons: GLP-1 demand headwind, slow top-line growth. ➡️ Trade KO at Charles Schwab
3. Procter & Gamble (PG)
Pricing-led growth has flattened, but margin recovery is intact. The 60+ year increase record makes PG the cleanest staple compounder in the index.
Pros: Brand portfolio, pricing power, capital returns discipline. Cons: Mature category growth, FX exposure. ➡️ Trade PG at E*TRADE
4. AbbVie (ABBV)
Past the Humira cliff, with Skyrizi and Rinvoq tracking above prior expectations. The 7.5% dividend CAGR over five years is the fastest on this list among large pharma.
Pros: New-product ramp, durable IP, attractive yield. Cons: Concentration in immunology, US drug pricing risk. ➡️ Trade ABBV at Robinhood
5. Chevron (CVX)
Best balance sheet in major oil. With 4.1% yield and a buyback that flexes to crude price, total shareholder yield often clears 7%.
Pros: Capital discipline, buyback flexibility, integrated model. Cons: Commodity exposure, energy transition headwinds. ➡️ Trade CVX at Webull
6. Altria (MO)
A controversial inclusion. The 7.8% yield is real, the FCF coverage holds, and ESG-driven selling has historically been a buying opportunity.
Pros: Highest yield on list, durable cash flows, buyback program. Cons: Volume decline, regulatory risk, ESG screening pressure. ➡️ Trade MO at Public
7. Realty Income (O)
The “Monthly Dividend Company” remains the bellwether net-lease REIT. AFFO-based payout near 76% with 27+ years of increases is hard to replicate.
Pros: Monthly distributions, tenant diversification, scale advantages. Cons: Rate sensitivity, REIT taxation in taxable accounts. ➡️ Trade O at SoFi Invest
8. IBM (IBM)
Software mix shift is finally lifting margins, and the dividend has grown for 30+ years. Growth has been slow, but the yield plus modest growth still clears the bar.
Pros: Software pivot, free cash flow, dividend track record. Cons: Slow top-line growth, legacy services drag. ➡️ Trade IBM at Interactive Brokers
9. AT&T (T)
Post-WarnerMedia, T is back to being a fiber and wireless utility. The 5.6% yield is well-covered after the dividend reset, but the prior cut hurts the long-term track record.
Pros: High current yield, simplified business, stable cash flow. Cons: Prior dividend cut, capex intensity, slow subscriber growth. ➡️ Trade T at M1 Finance
10. Kimberly-Clark (KMB)
Lower volatility consumer staple with a 50+ year increase record. The yield is decent, the growth is modest, and the business is recession-resistant.
Pros: Defensive cash flows, dividend longevity, brand portfolio. Cons: Mature growth, input cost exposure. ➡️ Trade KMB at Vanguard
Coverage and Risk Snapshot
| Ticker | FCF Cover | Net Debt/EBITDA | 10-Yr Total Return (Ann.) | Beta |
|---|---|---|---|---|
| JNJ | 2.1x | 0.8x | 8.4% | 0.6 |
| KO | 1.6x | 1.6x | 9.1% | 0.6 |
| ABBV | 1.9x | 2.4x | 14.2% | 0.7 |
| CVX | 1.7x | 0.4x | 11.5% | 1.1 |
| MO | 1.3x | 2.0x | 6.8% | 0.5 |
| O | 1.3x (AFFO) | 5.5x | 7.2% | 0.8 |
| IBM | 1.5x | 2.1x | 5.4% | 0.7 |
How to Build a Dividend Portfolio — 5 Tips
- Aim for at least 12 holdings across 6 sectors to avoid single-stock or sector concentration risk.
- Hold REITs and high-yield names in IRAs to defer tax on non-qualified distributions.
- Use a 4% FCF coverage minimum as your safety threshold; ignore yields above 8% without it.
- Prioritize 5%+ dividend CAGR over headline yield — growth compounds, yield doesn’t.
- Reinvest dividends until you actually need the income; the compounding is significant.
Recommended Offers
💡 Editor’s pick: Schwab is our default for dividend portfolios. The screener is excellent, DRIP is automatic, and the platform handles partial-share reinvestment cleanly.
💡 Editor’s pick: Fidelity matches Schwab on costs and pulls ahead on research. The dividend research reports for individual names are the best in the industry.
💡 Editor’s pick: M1 Finance is unmatched if you want a 15-stock dividend pie that auto-rebalances and reinvests cash on a fixed schedule.
FAQ — Best Dividend Stocks for 2026
Q: Is a 7%+ yield safe? A: Sometimes. The market is pricing risk into the yield, so look at FCF coverage and payout ratio. MO and T currently clear our threshold; many comparable yields do not.
Q: Are dividend stocks better than bonds at 4% Treasuries? A: They serve different roles. Bonds give certainty; dividend stocks give growth. Most retired investors hold both.
Q: Should I focus on yield or dividend growth? A: For accumulators, growth wins. For retirees, a blend of both. Avoid the trap of buying only the highest yields — they often signal distress.
Q: How are dividends taxed? A: Qualified dividends are taxed at long-term capital-gains rates (0%/15%/20%). Most names on this list pay qualified dividends; REIT distributions are mostly non-qualified.
Q: What’s a dividend aristocrat? A: An S&P 500 company with at least 25 consecutive years of dividend increases. JNJ, KO, PG, and KMB qualify; ABBV and MO do not yet.
Q: How often should I reposition the portfolio? A: Annually for most investors. Sell only on dividend cuts, payout ratio breaches, or fundamental deterioration — not on price.
Related Reading on Finace Stoks
- Best Stocks to Buy in 2026: Top 10 Picks
- Best Blue-Chip Stocks for 2026
- Growth vs Value Stocks: 2026 Comparison
- Best Bonds to Invest in 2026
- Asset Allocation Guide
Final Verdict
The cleanest five-stock dividend starter in 2026 is JNJ, KO, ABBV, CVX, and O. That mix gives roughly 3.8% blended yield, sector diversification across healthcare, staples, energy, and real estate, and a five-year dividend CAGR of about 5.5%. Layer in IBM and PG once those positions are full, and you have a defensible income portfolio for the current rate regime.
This article is for informational purposes only and is not investment advice. Stock prices, dividends, and market data are accurate as of publication and subject to change. Investing involves risk including loss of principal. Finace Stoks may receive compensation for some placements; rankings are independent.
By Finace Stoks Editorial · Updated May 9, 2026
- stock market
- dividend stocks
- 2026
- investing